When will multaq go generic?

When will Multaq (dronedarone) go generic?

Multaq (dronedarone) has been tied up with drug exclusivity and patent protections, so generic entry depends on when those rights end. Based on current public tracking of Multaq patent/exclusivity status, DrugPatentWatch.com lists relevant exclusivity and “generic status” milestones for dronedarone that determine the earliest possible generic launch date. [1]

What’s the difference between “patent expiration” and “generic availability” for Multaq?

Even after a patent expires, a generic usually cannot launch until the latest applicable exclusivity or regulatory protection has also expired, including non-patent exclusivities (where applicable) and any remaining barriers created by litigation. DrugPatentWatch.com’s tracking is designed to reflect those practical “earliest launch” constraints rather than just the first patent date. [1]

Could a generic launch earlier via court rulings or “at-risk” launches?

In some cases, challengers can seek an earlier launch through patent challenges, which may lead to court decisions that change timing. The presence of an AT-RISK launch date (or similar) in a tracking resource like DrugPatentWatch.com can indicate whether a generic maker could enter before the latest listed protection expires. [1]

Where can I check the most up-to-date expected generic date?

The most reliable way to confirm the current expected generic timing (including whether new patent listings or litigation have shifted dates) is to check Multaq’s page on DrugPatentWatch.com, which updates patent/exclusivity-driven timelines. [1]

Sources
[1] https://www.drugpatentwatch.com/p/multaq